Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 466
- Registration Number
- NCT05312879
- Locations
- 🇺🇸
Alabama Kidney Research, Alabaster, Alabama, United States
🇺🇸EmVenio Research, Chicago, Illinois, United States
🇺🇸Cardiology, P.C., Birmingham, Alabama, United States
Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 307
- Registration Number
- NCT05274269
- Locations
- 🇦🇹
Medizinische Universität Innsbruck, Innsbruck, Austria
🇧🇪Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Brussel - Campus Jette, Brussels, Belgium
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 71
- Registration Number
- NCT05153317
- Locations
- 🇺🇸
Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Children's Hospital of Colorado, Aurora, Colorado, United States
A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 86
- Registration Number
- NCT05111145
- Locations
- 🇦🇺
The Prince Charles Hospital, Chermside, Australia
🇦🇺Alfred Hospital, Melbourne, Australia
🇦🇺Institute for Respiratory Health, Nedlands, Australia
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: IVADrug: Placebo (matched to ELX/TEZ/IVA)Drug: Placebo (matched to VX-121/TEZ/D-IVA)Drug: Placebo (matched to IVA)
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 597
- Registration Number
- NCT05076149
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty
- Conditions
- Acute Pain
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 303
- Registration Number
- NCT05034952
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Lotus Clinical Research, Pasadena, California, United States
🇺🇸Chesapeake Research Group, Pasadena, Maryland, United States
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: IVADrug: Placebo (matched to ELX/TEZ/IVA)Drug: Placebo (matched to VX-121/TEZ/D-IVA)Drug: Placebo (matched to IVA)
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 435
- Registration Number
- NCT05033080
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
- Conditions
- Acute Pain
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 274
- Registration Number
- NCT04977336
- Locations
- 🇺🇸
Shoals Medical Trials Inc., Sheffield, Alabama, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Anaheim Clinical Trials, Anaheim, California, United States
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)
- First Posted Date
- 2021-07-20
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 82
- Registration Number
- NCT04969224
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺The Prince Charles Hospital, Chermside, Australia
🇦🇺Alfred Hospital, Melbourne, VIC, Australia
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 51
- Registration Number
- NCT04923464
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Central Florida Pulmonary Group, P.A., Orlando, Florida, United States